首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1615901

介入性心臟病學和周邊血管器械市場：按產品類型、應用、最終用戶和地區劃分，2024-2031 年

Interventional Cardiology and Peripheral Vascular Devices Market By Product Type, Application, End-User, & Region for 2024-2031

出版日期: 2024年07月19日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

介入性心臟病學和周邊血管器械市場評估 - 2024-2031

全球心血管疾病的增加增加了對微創治療的需求。特別是在已開發國家，人口老化和心臟病和血管疾病發病率較高需要先進的醫療幹預措施，預計2024年市場發展將超過240.8億美元，並預計到2031年將增長。 436.4億美元。

此外，持續的技術進步，例如藥物洗脫支架、生物可吸收血管支架和新的基於導管的技術的開發，正在提高這些手術的功效和安全性。不斷上漲的醫療保健成本以及人們對心血管疾病早期檢測和治療益處的認識不斷提高，正在推動市場成長，預計 2024 年至 2031 年複合年增長率約為 8.51%。

介入性心臟病學和周邊血管器械市場定義/概述

介入性心臟病學和周邊血管裝置是專門的醫療器械和植入物，用於診斷和治療影響心臟血管和周邊動脈的疾病。支架、導管、球囊和導引線是用於治療冠狀動脈疾病、週邊動脈疾病和其他血管疾病的微創手術中使用的裝置。使用這些設備對於恢復血流而無需進行開放性手術、降低心臟病發作風險和改善患者預後至關重要。由於技術進步、世界人口老化以及心血管疾病盛行率的增加，這個市場的未來充滿希望。持續的技術創新，例如生物可吸收支架和藥物洗脫技術的開發，以及新興市場醫療保健基礎設施的擴展，預計將推動這些設備的全球成長和採用。

對微創治療的需求不斷增長將推動介入性心臟病學和周邊血管器械市場？

對微創手術的需求不斷增長預計將推動介入性心臟病學和周邊血管器械市場。與傳統的開放性手術相比，使用支架、球囊和導管等微創技術具有許多優勢，包括更快的恢復時間、更短的住院時間和更低的併發症發生率。由於心血管疾病仍然是全球死亡的主要原因，醫療保健產業越來越依賴侵入性較小的先進手術來改善患者的治療結果。這些手術在慢性心臟病常見的已開發國家的老年人中尤其受歡迎。

2024 年 6 月，美敦力 (Medtronic) 獲得 FDA 核准用於治療週邊動脈疾病的新型微創球囊導管。該設備能夠在對周圍組織影響最小的情況下進行精確治療，凸顯了血管治療中非侵入性解決方案的成長趨勢。 2024年5月，Boston scientific也推出了最新的藥物洗脫支架。該支架旨在減少冠狀動脈再狹窄，並為心臟直視手術提供更安全、更有效的替代方案。

2024 年 3 月，歐洲藥品管理局 (EMA) 意識到快速獲得救生技術的迫切需求，宣佈了新的法規，以加快微創心血管設備的審批流程。這些政策旨在鼓勵更多企業在介入性心臟病學領域進行創新。總體而言，隨著世界各地的醫療保健系統優先考慮患者安全和成本效益，對微創手術的需求預計將推動介入性心臟病學和周邊血管設備市場的成長。

先進醫療設備的高成本是否會阻礙介入性心臟病學和周圍血管設備市場的成長？

先進醫療設備的高成本限制了介入性心臟病學和周邊血管設備市場的成長。這些醫療器材包括藥物洗脫支架、生物可吸收血管支架和先進導管等尖端技術，通常價格昂貴，因為它們需要廣泛的研究和開發以及監管審批流程。這可能會減少獲得這些醫療設備的機會，特別是在衛生預算有限且患者自付費用過高的發展中國家。因此，在成本敏感的市場中，這些先進設備的採用可能會被推遲。

高成本也會影響醫療保健提供者，他們必須權衡使用尖端技術的好處與機構的財務限制。醫院和診所，特別是在公共衛生系統和報銷率較低的地區，可能面臨預算限制，限制其投資新的昂貴設備的能力。因此，患者接受的醫療服務品質可能因地理位置或社會經濟地位而存在差異，這可能會阻礙整體市場的成長。

此外，先進醫療設備的高成本會抑制產業創新。如果公司認為成本問題會限制產品市場，他們可能不願意投資新技術的開發。因此，重點可能是現有設備的漸進式改進，而不是突破性創新。從長遠來看，先進設備的高成本可能會阻礙廣泛採用最有效和創新的治療方法，從而限制介入性心臟病學和周邊血管設備市場的成長潛力。

The rising global prevalence of cardiovascular diseases is driving up demand for minimally invasive procedures. The aging population, particularly in developed countries, is contributing to a higher incidence of heart and vascular diseases, necessitating advanced medical interventions evolving the market growth surpassing USD 24.08 Billion in 2024 and reachUSD 43.64 Billion by 2031.

Furthermore, ongoing technological advancements, such as the development of drug-eluting stents, bioresorbable vascular scaffolds, and novel catheter-based technologies, improve the efficacy and safety of these procedures. Increasing healthcare spending and growing awareness of the benefits of early detection and treatment of cardiovascular diseases help to drive market growth is expected to grow at aCAGR of about 8.51% from 2024 to 2031.

Interventional Cardiology and Peripheral Vascular Devices Market: Definition/ Overview

Interventional cardiology and peripheral vascular devices are specialized medical instruments and implants used to diagnose and treat conditions affecting the heart's blood vessels and peripheral arteries. Stents, catheters, balloons, and guidewires are among the devices used in minimally invasive procedures to treat coronary artery disease, peripheral artery disease, and other vascular disorders. The use of these devices is critical for restoring blood flow, lowering the risk of heart attack, and improving patient outcomes without the need for open surgery. The future of this market looks promising, thanks to technological advancements, an aging global population, and an increasing prevalence of cardiovascular diseases. Continued innovation, such as the development of bioresorbable stents and drug-eluting technologies, while expanding healthcare infrastructure in emerging markets are expected to drive the growth and adoption of these devices globally.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Demand for Minimally Invasive Procedures Propel the Interventional Cardiology And Peripheral Vascular Devices Market?

The growing demand for minimally invasive procedures is expected to propel the interventional cardiology and peripheral vascular devices market. In comparison to traditional open surgeries, minimally invasive techniques, such as the use of stents, balloons, and catheters, provide numerous advantages, including shorter recovery times, shorter hospital stays, and lower complication rates. As cardiovascular diseases remain a leading cause of death worldwide, the healthcare industry is increasingly relying on advanced, less invasive procedures to improve patient outcomes. These techniques are particularly popular among the elderly in developed countries, where chronic heart disease is common.

In June 2024, Medtronic received FDA approval for a new minimally invasive balloon catheter used to treat peripheral artery disease. This device enables precise treatment with minimal impact on surrounding tissue, highlighting the growing trend of non-invasive solutions in vascular care. In May 2024, Boston Scientific also introduced its latest drug-eluting stent, which is intended to reduce restenosis in coronary arteries while providing a safer and more effective alternative to open-heart surgery.

In March 2024, the European Medicines Agency (EMA) announced new regulatory initiatives to speed up the approval process for minimally invasive cardiovascular devices, recognizing the critical need for quicker access to life-saving technologies. These policies are intended to encourage more companies to innovate in the field of interventional cardiology. Overall, as healthcare systems around the world prioritize patient safety and cost-effectiveness, the demand for minimally invasive procedures is expected to fuel growth in the interventional cardiology and peripheral vascular devices market.

Will High Cost of Advanced Medical Devices Hinder the Growth of the Interventional Cardiology and Peripheral Vascular Devices Market?

The high cost of advanced medical devices limits the growth of the interventional cardiology and peripheral vascular devices market. These devices, which include cutting-edge technologies such as drug-eluting stents, bioresorbable vascular scaffolds, and advanced catheters, are often expensive due to the extensive research, development, and regulatory approval processes required. This can make these devices less accessible, especially in developing countries where healthcare budgets are limited and patients' out-of-pocket costs are prohibitively high. As a result, adoption of these advanced devices may be slower in markets where cost is an important consideration.

The high cost also affects healthcare providers, who must weigh the benefits of using cutting-edge technologies against their institutions' financial constraints. Hospitals and clinics may face budgetary constraints that limit their ability to invest in costly new devices, particularly in public healthcare systems or in areas with lower insurance reimbursement rates. This can result in disparities in the quality of care available to patients based on their geographical location or socioeconomic status, potentially impeding overall market growth.

Furthermore, the high cost of advanced medical devices can stifle innovation in the industry. Companies may be hesitant to invest in the development of new technologies if they believe the market for these products is constrained by cost concerns. This could result in an emphasis on incremental improvements to existing devices rather than ground-breaking innovations. In the long run, the high cost of advanced devices may act as a barrier to widespread adoption of the most effective and innovative treatments, limiting the growth potential of the interventional cardiology and peripheral vascular devices market.

Category-Wise Acumens

Will Rising Demand for Drug-Eluting Stents (DES) Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The increasing demand for drug-eluting stents (DES) is expected to drive significant growth in the interventional cardiology and peripheral vascular devices market. DES are becoming dominant due to their effectiveness in preventing restenosis, which is the re-narrowing of arteries following stent placement. These stents are coated with medication that is slowly released to reduce inflammation and the likelihood of artery reblockage, making them a better option than bare-metal stents. The benefits of DES, such as improved patient outcomes and fewer repeat procedures, are consistent with the growing global emphasis on effective and long-lasting cardiovascular treatments.

In June 2024, the European Medicines Agency (EMA) issued new guidelines to expedite the approval process for advanced cardiovascular devices, including DES. This move is intended to improve patients' access to innovative treatments throughout Europe. In May 2024 In the United States, the Food and Drug Administration (FDA) announced an initiative to increase funding for clinical trials examining the efficacy of DES in diverse populations, demonstrating a commitment to advancing the development and accessibility of these critical devices. These regulatory actions highlight the importance of DES in the cardiovascular market and support its continued expansion.

Chronic Total Occlusion (CTO) Devices are the fastest-growing segment of the market. The increasing prevalence of complex coronary artery disease, as well as technological advancements that improve the success rates of CTO procedures, are driving this growth. CTO devices are intended to treat long-term blockages in coronary arteries that have proven resistant to conventional treatments. The development of more effective and less invasive CTO devices is accelerating their adoption, reflecting a larger trend toward better solutions for difficult vascular conditions.

Will Rising Prevalence of Coronary Artery Diseases Dominate the Interventional Cardiology And Peripheral Vascular Devices Market?

Rising incidences of coronary artery disease (CAD) are expected to initiate its dominance in the interventional cardiology and peripheral vascular devices market. CAD is one of the most common cardiovascular diseases in the world, owing primarily to rising risk factors such as aging populations, unhealthy lifestyles, and high obesity and diabetes rates. As CAD remains a leading cause of morbidity and mortality, there is a steady and growing demand for advanced medical devices designed to treat it. These devices, which include drug-eluting stents, coronary balloons, and advanced catheter systems, are critical for managing and alleviating the effects of CAD. The consistently high demand for these technologies demonstrates their market dominance.

In June 2024, the US Centers for Disease Control and Prevention (CDC) announced a new initiative aimed at lowering the incidence of cardiovascular disease by improving access to innovative interventional technologies. This initiative includes funding for hospitals to acquire advanced CAD treatment devices as well as enhanced healthcare provider training. Furthermore, in May 2024, the European Society of Cardiology (ESC) updated its guidelines to emphasize the use of cutting-edge interventional devices in CAD management, reflecting a growing recognition of the importance of these technologies in improving patient outcomes. These developments highlight the importance of CAD in driving market trends, as well as the ongoing focus on improving treatment options for this common condition.

Peripheral Artery Disease (PAD) is the most rapidly growing application segment. PAD's rapid growth is attributed to an aging population, rising diabetes rates, and increased awareness of the condition. PAD, which affects blood flow to the limbs, is becoming more common as lifestyle risk factors increase. Advances in treatment technologies, such as new-generation balloon catheters and atherectomy devices designed specifically for PAD, are driving market growth in this area. The emphasis on improving patient outcomes and expanding treatment options for PAD is fueling this segment's rapid growth.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The advanced healthcare infrastructure in North America is a major driver of the interventional cardiology and peripheral vascular devices market. This region, with its well-established healthcare systems, cutting-edge medical facilities, and high healthcare expenditure, is an ideal environment for the adoption of advanced medical technologies. The presence of leading healthcare institutions and research centers promotes innovation and early adoption of new cardiovascular devices, which are essential for treating heart disease and peripheral vascular conditions. As cardiovascular diseases continue to be the leading cause of death in North America, the demand for these devices grows, driven by the need for effective and minimally invasive therapies.

The United States government has also played an important role in this development. In April 2024, the Centers for Medicare and Medicaid Services (CMS) implemented new reimbursement policies for advanced cardiovascular procedures, making these life-saving interventions more accessible to a larger patient population. This policy shift is expected to increase the adoption of interventional cardiology and peripheral vascular devices in North America, bolstering the region's global market leadership. North America's strong healthcare system, government support, and continuous innovation position it as a market leader.

Will Increasing Incidence of Cardiovascular Conditions in Asia-Pacific Propel the Interventional Cardiology and Peripheral Vascular Devices Market?

The rising prevalence of cardiovascular diseases in Asia-Pacific is expected to drive rapid growth of this region in the interventional cardiology and peripheral vascular devices market. The prevalence of cardiovascular diseases in Asia-Pacific is rapidly increasing, owing to factors such as aging populations, unhealthy diets, sedentary lifestyles, and rising hypertension and diabetes rates. This increase in cardiovascular conditions is driving up demand for advanced medical devices that can effectively treat and manage these diseases, particularly through minimally invasive procedures. As a result, Asia-Pacific's interventional cardiology and peripheral vascular device markets are expected to grow significantly.

In June 2024, Medtronic announced that it had expanded its operations in India and China, two of Asia-Pacific's largest markets, to increase the availability of its most recent stents and balloon catheters. This move aims to meet the growing demand for cardiovascular treatments in these countries, where the prevalence of heart disease is rapidly increasing. Similarly, in July 2024, Boston Scientific launched a new series of drug-eluting stents in the Asia-Pacific market, specifically designed to meet the region's unique patient needs. These developments emphasize the importance of the Asia-Pacific market for major medical device manufacturers, as well as the region's growing role in the global healthcare landscape.

Asia-Pacific countries are taking proactive measures to address the rising cardiovascular disease burden. For instance, in May 2024, the Chinese government announced a new initiative to improve heart disease prevention and treatment using advanced medical technologies. This initiative includes financial incentives for hospitals to purchase cutting-edge interventional cardiology devices, as well as training programs for healthcare professionals to improve their skills in using these devices. Similarly, in April 2024, the Indian government announced that it would expand its National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), with a focus on increasing access to life-saving cardiovascular interventions. These government efforts are expected to increase the adoption of interventional cardiology and peripheral vascular devices in Asia-Pacific, driving significant market growth.

Competitive Landscape

The competitive landscape of the interventional cardiology and peripheral vascular devices market is characterized by a mix of emerging players, regional manufacturers, and specialized companies focusing on niche segments. These competitors are leveraging innovative technologies and strategic partnerships to gain market share, particularly in areas like drug-eluting stents, atherectomy devices, and bioresorbable vascular scaffolds. Companies are also increasingly focusing on developing cost-effective solutions to cater to price-sensitive markets, particularly in emerging economies. Additionally, the market sees continuous product launches and FDA approvals, with smaller firms often introducing novel devices that address specific clinical needs, thus intensifying competition.

Some of the prominent players operating in the interventional cardiology and peripheral vascular devices market include:

Abbott Laboratories

Braun Melsungen AG

Biotronik SE & Co. KG

Boston Scientific Corporation

R. Bard (BD)

Cardinal Health, Inc.

Cook Medical, Koninklijke Philips N.V.

Medtronic plc

Teleflex, Inc.

Terumo Group

L. Gore & Associates, Inc.

Latest Developments

In May 2024, Abbott introduced a new bioresorbable stent in Europe, marking a significant step forward in interventional cardiology. The stent is intended to dissolve gradually, minimizing the long-term complications associated with traditional metal stents.

In April 2024, Terumo introduced a new peripheral guidewire in Japan with the goal of improving intervention precision in complex vascular cases. This product launch is part of Terumo's strategy to broaden its offerings in the peripheral vascular device market.

In January 2024, BD received CE mark approval for its most recent vascular access device, which includes advanced antimicrobial technology to reduce infection risks during interventional procedures. This development demonstrates BD's commitment to innovation in the peripheral vascular space.

In February 2024, Cardinal Health introduced a new line of vascular closure devices in the United States, designed to reduce bleeding complications following interventional procedures. This product line is intended for hospitals seeking cost-effective and efficient closure solutions.

In March 2022, Philips announced the acquisition of a leading vascular imaging software firm, expanding its image-guided therapy portfolio. This acquisition is expected to help Philips improve its capabilities in both interventional cardiology and peripheral vascular interventions.